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The success of molecular targeted therapy in cancer may depend on
the selection of appropriate tumor types whose survival depends
on the drug target, so-called ‘‘oncogene addiction.’’ Preclinical
approaches to defining drug-responsive subsets are needed if
initial clinical trials are to be directed at the most susceptible
patient population. Here, we show that gastric cancer cells with
high-level stable chromosomal amplification of the growth factor
receptor MET are extraordinarily susceptible to the selective in-
hibitor PHA-665752. Although MET activation has primarily been
linked with tumor cell migration and invasiveness, the amplified
wild-type MET in these cells is constitutively activated, and its
continued signaling is required for cell survival. Treatment with
PHA-665752 triggers massive apoptosis in 5 of 5 gastric cancer cell
lines with MET amplification but in 0 of 12 without increased gene
copy numbers (P  0.00016). MET amplification may thus identify
a subset of epithelial cancers that are uniquely sensitive to disrup-
tion of this pathway and define a patient group that is appropriate
for clinical trials of targeted therapy using MET inhibitors.
gene amplification  molecular marker  oncogene addiction  targeted
therapy
Genetic events that arise and are selected during tumorprogression may become essential for tumor survival, a
phenomenon generally described as ‘‘oncogene addiction’’ (1).
The recent success of molecularly targeted agents in the treat-
ment of human cancer appears to depend on the clear identifi-
cation of drug targets that drive tumorigenesis in subsets of
tumors. As such, imatinib (Gleevec) is highly effective in chronic
myeloid leukemia cells harboring the BCR-ABL translocation,
gastrointestinal stromal tumor cells with activating mutations of
C-KIT, and chronic myelomonocytic leukemia cells with rear-
rangements of the platelet-derived growth factor receptor, all of
which are effectively targeted by the inhibitor (2–4). Similarly,
most non-small-cell lung cancers (NSCLC) with activating mu-
tations in the epidermal growth factor receptor (EGFR) appear
to be highly sensitive to treatment with the specific EGFR
inhibitors gefitinib (Iressa) and erlotinib (Tarceva) (5–7). Col-
lectively, these observations have suggested that genetically
defined subsets of cancers may share dependence on a specific
signaling pathway and that small-molecule inhibitors targeting
these pathways would be most effectively tested in patient
populations identified by appropriate molecular markers.
Clues to the identity of genes that are critical to tumor growth
and survival and, hence, may serve as therapeutic targets, have
emerged from analysis of gross chromosomal rearrangements,
including allelic gains and losses. The most striking example is
amplification of a locus on chromosome 17q, found in 30% of
all breast cancers, which targets the HER2 (ERBB2) growth
factor receptor (8). Although overexpression of HER2 in breast
cancer is associated with an adverse prognosis, response to
Herceptin, an antibody targeting the receptor, is specifically
correlated with tumors that have high-level HER2 gene ampli-
fication (9). In searching for additional genetic markers that may
be correlated with therapeutic response, we analyzed an inhib-
itor of MET, a growth factor receptor known to be activated in
subsets of epithelial cancers and linked to cancer cell migration
and tumor invasiveness. A fraction of gastric cancer cell lines
appears to be exquisitely sensitive to inhibition of MET signaling
using a specific tyrosine kinase inhibitor. In these cells, which are
marked by high-level amplification of wild-type MET, constitu-
tive activation of the receptor drives proliferative and survival
signals. The preclinical identification of patients with such a
responsive tumor subset may guide early-phase clinical trials of
MET inhibitors, particularly in gastric cancer, where 10–20% of
primary tumors are known to have MET amplification (10–12).
Results and Discussion
Screening of Cancer Cell Lines for Sensitivity to a MET Tyrosine Kinase
Inhibitor. The genetic heterogeneity underlying differential re-
sponsiveness of lung cancers to the EGFR tyrosine kinase
inhibitors gefitinib and erlotinib is recapitulated in lung-cancer-
derived cell lines. Whereas most NSCLC cell lines have an IC50
for gefitinib of 10 M, rare cell lines harboring activating
mutations in EGFR typically demonstrate a 50- to 100-fold
enhancement in sensitivity, as measured by cell killing (6, 13–15).
To test the predictive value of such an in vitro drug-sensitivity
screen, we treated 40 cell lines representing diverse tumor types
with gefitinib at concentrations ranging from 100 nM to 10 M.
Extreme sensitivity (100 nM) was observed with NCI-H1650, the
only NSCLC cell line in our panel with the del E746-A750
activating mutation in EGFR (Fig. 1) (14). Variable degrees of
sensitivity were evident in other cell lines tested, but none had
a degree of cell killing comparable to 1 M gefitinib. The
NCI-H1975 NSCLC cell line harbors both a L858R-sensitizing
mutation in EGFR and the T790M drug-resistance mutation,
and, hence, it scored as relatively resistant in the assay. Consis-
tent with the lower gefitinib sensitivity of the remaining cell lines,
they did not harbor activating EGFR mutations. To extend this
analysis to other tyrosine kinase inhibitors, we screened the same
cancer cell line panel for sensitivity to a specific MET tyrosine
kinase inhibitor PHA-665752 (16) (Pfizer). Extreme sensitivity
(100 nM) to this drug was observed for one gastric cancer cell
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line MKN45. As with gefitinib, other cell lines demonstrated
variable degrees of cell killing, but none had a similar response
1 M of PHA-665752 (Fig. 1). The MKN45 cell line is known
to have amplification ofMET (17), pointing to a potential genetic
mechanism underlying its extraordinary drug sensitivity. None of
the other 39 cell lines had MET gene amplification, as deter-
mined by quantitative PCR (qPCR) analysis (data not shown).
MET Amplification and Constitutive Activation in Human Gastric
Cancer Cells. Overexpression of MET has been reported in many
epithelial cancers, but gene amplification is most common in
gastric cancer, where 10–20% of all primary tumors and up to
40% of the scirrhous histological subtype have increased MET
gene copy numbers (10–12). Analysis of a panel of gastric cancer
cell lines by using qPCR identified increased MET gene copy
number in 5 of 17 (29%) cases (Fig. 2A). In all 5 cell lines, FISH
analysis showed the amplified gene copies to be integrated within
a chromosomal locus, consistent with so-called homogeneously
staining regions (HSRs) (Fig. 2B). HSR-amplification is char-
acteristically stable in the absence of selection, indicating that
the increased MET gene copy number represents targeted
amplification of this locus rather than reflecting general aneu-
ploidy. FISH and qPCR analyses were consistent in identifying
the subset of cell lines with MET amplification, with higher fold
amplification apparent by FISH (Fig. 2 A and B), presumably
reflecting the effect of low-level copy-number variability in the
control locus used in qPCR analysis, resulting in underestimation
of the true extent of MET amplification. A cutoff of 8-fold gene
amplification, as measured by qPCR, provided a clear distinction
between gastric cancer cells with low-level aneuploidy (Amp)
versus those with high-level specific HSR-amplification of MET
(Amp).
As expected, all 5 Amp cells displayed dramatic elevation in
MET protein expression, compared with the 12 Amp cells (Fig.
3A). Remarkably, Amp cells also displayed high levels of
baseline MET activation, as measured by phosphorylation of
tyrosine residues 1,2341,235 and 1,349 (Fig. 3A). MET phos-
phorylation was not due to the presence of activating mutations,
as determined by nucleotide sequencing of the entire coding
sequence in all 17 gastric cancer cell lines (data not shown).MET
activation in Amp cells also appeared to be independent of its
ligand, hepatocyte growth factor (HGF)scatter factor, based on
three observations. First, whereas Amp cells had low levels of
MET phosphorylation under standard culture conditions but
Fig. 1. Drug sensitivity profile of 40 human cancer cell lines treated with gefitinib or PHA-665752. Cells were cultured and analyzed in triplicate within microtiter
plates. Cell numbers were quantitated by DNA staining, 3 days after addition of various concentrations of drugs and expressed as a fraction of matched untreated
cultures. For each drug concentration, cell lines with relative drug sensitivity (50% of untreated control growth) are shown in red, intermediate sensitivity
(50–75%) in yellow, and drug insensitivity (75%) in green. Arrowheads denote cell lines with unique drug sensitivity to gefitinib (NCI-H1650) or to PHA-665752
(MKN45).
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demonstrated HGF-induced receptor autophosphorylation ac-
companied by phosphorylation of downstream effectors
ERK12 and AKT, no such increase in baseline MET phos-
phorylation or activation of downstream signaling was evident in
Amp cells treated with HGF (Fig. 3B). Second, noHGFmRNA
expression was detectable by quantitative RT-PCR in 4 of 5
Amp cell lines (see Table 1, which is published as supporting
information on the PNAS web site), arguing against an autocrine
signaling loop. Finally, treatment of Amp cells with neutralizing
anti-HGF antibody did not affect the levels of MET phosphor-
ylation (Fig. 3C), whereas it effectively suppressed HGF-induced
MET activation in Amp cells (Fig. 3D). Thus, Amp cells
appear to exhibit constitutive ligand-independent MET activa-
tion, which may result from receptor dimerization associated
with the very high levels of protein expressed on the cell surface,
an effect that has been reported forMET (18) and other receptor
tyrosine kinases (19).
MET Amplification As Molecular Marker of Susceptibility to a Tyrosine
Kinase Inhibitor. To test the potential therapeutic relevance of
these observations, we treated gastric cancer cell lines with the
specific MET kinase inhibitor PHA-665752. This small-molecule
inhibitor has an IC50 against MET of 9 nM, compared with an
IC50 of 3.8 M and 10 M for EGFR and platelet-derived
growth factor receptor, respectively (16). In 5 of 5 Amp cells,
treatment with PHA-665752 for 96 h resulted in a dramatic
reduction in cell numbers, whereas treatment had no effect in
any of the 12 Amp cells (P  0.00016, Fisher’s exact test,
two-sided) (Fig. 4A; and see Table 2, which is published as
supporting information on the PNAS web site). Cell viability for
these experiments was assessed by vital dye staining and ex-
Fig. 3. Constitutive activation of MET in Amp cells. (A) MET is constitutively
activated in the Amp cells. Immunoblotting analysis, demonstrating high
levels of MET protein expression in two representative Amp cell lines, com-
pared with two Amp cell lines. Immunoblotting using two phospho-specific
MET antibodies (against Y12341235 and Y1349) shows strong baseline phos-
phorylation of the receptor only in Amp cells (-actin loading control). (B)
Effect of HGF on MET activation in Amp and Amp cells. Representative
immunoblotting analysis of cells serum-starved for 24 h and treated with 40
ngml HGF for 10 min. Phosphorylation of MET (Y12341235) is induced by
HGF in Amp cells, but it is unaltered in Amp cells treated with HGF (total
MET expression in these cells is shown as control). Phosphorylation of the
downstream effectors ERK12 (T202Y204) and AKT (S473) is also strongly
induced in Amp cells treated with HGF but unaltered by HGF treatment in
Amp cells. Blots probed with phospho-specific antibodies were exposed for
a short time to illustrate signaling differences and to avoid potential signal
saturation associated with longer exposure times. (C) Neutralizing HGF anti-
body does not affect MET activation in Amp cells. Representative Western
blot, demonstrating unaltered baseline activation of MET in Amp cells
(MKN45) treated with neutralizing anti-HGF antibody. Cells were serum
starved for 24 h and subsequently treated with 5 gml anti-HGF antibody or
goat IgG control in serum-free media for another 24 h, by using standard
conditions for neutralization of HGF (30). (D) Neutralizing HGF antibody can
functionally inactivate HGF-mediated MET activation in Amp cells. As control
for C, Amp cells (AGS) were treated with HGF alone, with neutralizing
antibody to HGF, or goat IgG (control). Suppression of HGF-induced MET
activation in Amp cells confirms effective HGF neutralizing activity of this
anti-HGF antibody.
Fig. 2. MET genomic amplification in human gastric cancer cell lines. (A)
Human gastric cancer cell lines screened for the presence ofMET amplification
by using qPCR. The relative MET copy number is derived by comparison with
an unrelated control locus, TOP3A, at chromosome locus 17p11. Cell lines with
high-levelMET amplification (Amp) are shown in red, whereas the cells with
no or low-level copy number increase of MET (Amp) are shown in blue. All
Amp cells have HSR-amplification of MET. (B) Representative metaphase
(Upper) and interphase (Lower) FISH analysis of human gastric cancer cell lines,
showing amplification of MET within characteristic HSRs in Amp cells. In
SNU-5 cells (Amp) with high-level amplification, the MET signal (red) is
present in HSRs (red arrowhead) that are distinct from the endogenous gene
locus (chromosome 7q31, red arrow). Control probe on the opposite arm of
chromosome 7 (chromosome 7p21) is shown in green (green arrow). In KATO
III cells (Amp), the low-level increased MET gene copy number is associated
with five individual copies of chromosome 7 (aneuploidy).
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pressed as a fraction of viable cells in matched untreated
cultures. To determine whether this effect represented cell death
or growth arrest, we compared the effect of PHA-665752 on the
proliferation of Amp and Amp cells as a function of time.
Amp cells underwent an initial arrest in proliferation, followed
by cell death (Fig. 4B). In contrast, the proliferation rate of
Amp cells was unaffected by the presence or absence of
PHA-665752 (Fig. 4B).
To confirm that the differential effects of PHA-665752 are
truly attributable to its effect on MET, we transfected cells with
small interfering (si)RNA targeting theMET receptor transcript.
Effective and specific knockdown of MET protein expression
was demonstrated by immunoblotting analysis (Fig. 4C). As
control for nonspecific effects on growth factor signaling, we also
tested siRNA targeting EGFR and ERBB2. Consistent with the
effect of PHA-665752, a marked reduction in cell viability was
evident in Amp cells after MET knockdown, whereas no such
effect was observed in Amp cells (Fig. 4D). Amp cells were
not affected by knockdown of other receptors, such as EGFR or
ERBB2.
To address the mechanism by which PHA-665752 triggers cell
death in Amp cells, we first tested the effect of drug treatment
on MET-dependent signaling. PHA-665752 (50 nM) effectively
suppressed the constitutive MET autophosphorylation in Amp
cells (Fig. 5A). Most significantly, treatment with this concen-
tration of PHA-665752 also effectively abrogated the baseline
phosphorylation of downstream effectors of growth factor re-
ceptors, such as ERK12, AKT, STAT3, and FAK. Thus,
constitutive activation of these proliferative and survival path-
ways in Amp cells appears to depend specifically on baseline
MET signaling. In contrast, in Amp cells, where MET is not
constitutively autophosphorylated, PHA-665752 had no effect
on baseline phosphorylation of ERK12, AKT, STAT3, or FAK,
indicating that these effectors are likely to be activated through
alternative growth factor receptors (Fig. 5A).
Suppression of essential growth-factor-mediated survival
pathways has been linked to the induction of apoptosis. Consis-
tent with this model, both cleaved caspase-3-staining and PARP-
cleavage assays demonstrated apoptosis in Amp cells treated
with PHA-665752 but not in Amp cells under identical condi-
tions (Fig. 5 B and C). The early induction of apoptosis by
PHA-665752 in SNU-5 cells is accompanied by a prominent
PARP-cleavage signal at 72 h, compared with amore delayed but
prolonged cell death in MKN45 cells (Fig. 3B). Thus, a subset of
gastric cancer cell lines defined by targeted MET amplification
appears to depend on constitutive activation of this growth factor
receptor for their survival and show exquisite sensitivity to cell
killing by the tyrosine kinase inhibitor PHA-665752.
Concluding Remarks and Clinical Implications.Analysis of the role of
MET inmalignancy has largely focused on its effect in promoting
cell motility, invasion, and metastasis rather than its primary
transforming potential. However, the ability of MET itself to
drive tumorigenesis is evident from its central role in initiating
human papillary renal carcinoma (20) and in a number of mouse
models with ectopic expression of the activated receptor (21–23).
Fig. 4. Selective killing of gastric cancer cell lines with MET amplification after MET inhibition. (A) Sensitivity of Amp cells (red) and Amp cells (black) to
increasing concentrations of PHA-665752. Cells were grown for 96 h at various concentrations of PHA-665752, and their viability was assessed by using MTT assays.
Results are plotted as percent viability of treated cells compared with untreated matched controls. Experiments were performed in triplicate, with standard
deviations shown. (B) Growth curve of representative Amp and Amp cells treated with PHA-665752. Cells were grown for up to 6 days in the presence or
absence of PHA-665752 (1 M), and relative cell numbers were measured by using the fluorescent nucleic acid dye SYTO60 and expressed as a fraction of the
number of cells plated. Experiments were performed in triplicate, with standard deviations shown. (C) Effective knockdown of targeted receptor tyrosine kinases
by using siRNAs. Immunoblotting analysis of MET, EGFR, and ERBB2 protein levels after treatment of Amp and Amp cells with specific siRNAs for 48 h. The
relative exposure time of MET signal in Amp immunoblots was increased to demonstrate effectiveness of siRNA knockdown (-actin loading control). (D)
Selective killing of Amp cells after siRNA-mediated knockdown of MET. Viability in Amp and Amp cells, measured by using the MTT assay, was compared
96 h after knockdown of MET or unrelated receptors (EGFR and ERBB2). Cell viability is plotted as a percentage of cells treated with a nonspecific (control) siRNA
duplex. Experiments were performed in triplicate, with standard deviations shown.
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Our observations raise the possibility that, even in human
cancers, where MET deregulation may or may not be the
initiating genetic event, amplification of the gene encoding this
receptor may lead to dependence on its transduced signals (i.e.,
oncogene addiction), thereby identifying a potential target for
therapeutic intervention.
The use of panels of tumor-derived cell lines to identify
subtypes with extraordinary sensitivity to molecularly targeted
drugs may provide an effective functional screening approach in
the preclinical development of targeted agents. Although the
studies described here were limited to gastric cancer cell lines
cultured in vitro, the dramatic difference between Amp and
Amp cells is likely to also be evident in mouse xenograft
models. Interestingly, in its initial testing, PHA-665752 showed
effective killing in only one cell line in culture, GTL16, and it
induced marked tumor regression in mouse xenografts derived
from these cells (16). Of note, GTL16 is a gastric cancer cell line
with 10-fold MET amplification (24), consistent with our
proposed link between MET amplification and susceptibility to
MET inhibition. Clinical trials ofMET inhibitors, once available,
are now required to test this molecular correlation.
Our observations suggest that MET amplification in gastric
cancers may constitute an important molecular marker for
targeted therapy. As MET inhibitors enter the clinical arena in
the near future, our results would predict that patients with
gastric cancer positive for HSR-amplification of MET may
constitute a subset at high likelihood for drug response. Selection
of tumors in early-phase clinical trials that are readily genotyped
for markers such as HSR-amplification of MET may allow
demonstration of drug effectiveness while limiting the size of
patient cohorts required for such clinical studies. In contrast to
the large clinical trials of gefinitib involving unselected cases of
NSCLC that were required to demonstrate a small responsive
subset (25–28), this strategy relies on preclinical identification of
cancer types most likely to show a clinical response. If successful,
this approach to identifying critical molecular markers of drug
susceptibility may facilitate the clinical testing of targeted agents
in cancer therapy.
Materials and Methods
Cellular Proliferation and Viability Assays. Cells were plated in
96-well plates in medium containing 4% FBS at4,000 cells per
well and, after 24 h, treated with various concentrations of either
gefitinib or PHA-665752. For quantitation of cellular prolifer-
ation, cells were fixed at appropriate time points in 4% para-
formaldehyde, and all plates were stained simultaneously by
using the fluorescent nucleic acid stain SYTO60 (Molecular
Probes) at 1:8,000 dilution in PBS. Quantitation was done by
measuring the absorption at 700 nm by using the Odyssey
Imaging System (LI-COR, Lincoln, NE). The relative cell num-
ber was obtained by normalizing treated samples to matched
untreated specimens. For quantitation of cell viability, cultures
were stained after 4 days by using the MTT assay. Briefly, 10 l
of 5 mgml MTT (Thiazolyl blue) solution was added to each
well and incubated for 2 h at 37°C. For adherent cell lines, the
media was removed from each well, and the resultant MTT
formazan was solubilized in 100 l of DMSO. For nonadherent
cell lines, the MTT formazan was solubilized by direct addition
of 100 l of acidic isopropanol (0.1 N HCl) to each well. The
results were quantitated spectrophotometrically by using a test
wavelength of 570 nm and a reference wavelength of 630 nm.
FISH and Mutational Analysis. Bacterial artificial chromosome
clone CTD-1013N12, containing the full-length MET gene, was
used for FISH. PAC RP4–620P6, mapping to 7p21, was used as
a control probe. FISH was performed as described in ref. 29. For
mutational analysis, genomic DNA was amplified by PCR and
sequenced bidirectionally by using BigDye Terminator v1.1
chemistry (Applied Biosystems). Primer sequences and anneal-
ing temperatures are provided in Table 3, which is published as
supporting information on the PNAS web site.
siRNA-Mediated ‘‘Knockdown’’ of MET Expression and Immunoblot-
ting Analysis. The duplexes targeting MET, EGFR, and ERBB2
transcripts were custom SMARTpool mixtures fromDharmacon
(Lafayette, CO). siRNA duplexes were transfected by using
Lipofectamine 2000 from Invitrogen following the manufactur-
er’s instructions. Briefly, cells were plated in 4% serum and
transfected the next day with siRNAs at a final concentration of
40 nM for 5 h, followed by change of culture medium. The
transfection was repeated on day 2 under the same conditions.
Cell viability was assayed 4 days from the time of the first
transfection, by using the MTT assay.
Fig. 5. Suppression of MET-dependent signals by PHA-665752 in Amp cells and induction of apoptosis. (A) Immunoblotting analysis, demonstrating inhibition
of MET autophosphorylation (Y12341235) by PHA-665752. Abrogation of baseline phosphorylation of downstream effectors [ERK12 (T202Y204), AKT (S473),
STAT3 (Y727), and FAK (Y576Y577)] is evident after drug treatment in Amp cells but not in Amp cells. PHA-665752 was added for 3 h before protein extraction
(representative blots shown). (B) Induction of apoptosis in Amp cells, but not in Amp cells, 72 h after treatment with PHA-665752 (1M), measured by staining
for cleaved caspase-3 (green). Cells are costained with DAPI (blue) to show nuclei. (C) Immunoblotting analysis for PARP cleavage to demonstrate induction of
apoptosis in Amp cells, but not Amp cells, after treatment with PHA-665752 (500 nM for 72 h) (-actin loading control).
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Antibodies. The phospho-MET (Y1234Y1235), phospho-AKT
(S473), phopho-ERK12(T202Y204), phospho-FAK (Y576
Y577), phospho-STAT3 (Y727), AKT, ERK12, STAT3,
ERBB2, EGFR, cleaved PARP, and cleaved caspase-3 antibod-
ies were from Cell Signaling Technology (Beverly, MA). The
phospho-MET (Y1349) antibody was from BioSource Interna-
tional (Camarillo, CA). The total MET antibody (C-12) was
from Santa Cruz Biotechnology. The -actin antibody was from
Abcam (Cambridge, MA). The neutralizing HGF goat antibody
was from R & D Systems, and the matched goat IgG control
antibody was from Sigma. All immunoblots were done with
1:1,000 antibody dilution, except for the -actin antibody, which
was used at 1:10,000 dilution.
Apoptosis Induction Assay. Cells were plated on coverslips in
12-well dishes and grown to 75% confluency in 10% serum,
followed by incubation in 4% serum and PHA-665752. After
72 h, cells were fixed with 4% paraformaldehyde for 20 min,
permeabilized by using 1% Nonidet P-40 for 5 min, and blocked
with 3% BSA for 30 min. The coverslips were then incubated
overnight at 4°C with cleaved caspase-3 antibody at 1:200
dilution. The next day, the coverslips were washed three times
with PBS and incubated with a secondary antibody (goat anti-
rabbit FITC-conjugated) for 1 h at 1:250 dilution. After five
washes with PBS, coverslips were mounted in Vectashield
mounting medium containing DAPI (Vector Laboratories), and
staining was visualized by fluorescent microscopy.
Supporting Information. Further description of experimental pro-
cedures can be found in Supporting Materials and Methods, which
is published as supporting information on the PNAS web site.
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